Market Overview:
The global mouth-dissolving tablets market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of various diseases, rising demand for oral drugs, and technological advancements in the pharmaceutical industry. Based on type, the global mouth-dissolving tablets market is segmented into anti-psychotics drug, anti-epileptics drug, and other types. The anti-psychotics drug segment is expected to account for the largest share of the global mouth-dissolving tablets market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to an increase in demand for these drugs across regions worldwide. Based on application,the global mouth-dissolving tablets market is divided into CNS diseases, gastrointestinal diseases, CV diseases (cardiovascular diseases), and other applications segments.
Product Definition:
Mouth-dissolving tablets are a type of tablet that dissolves in the mouth, as opposed to traditional tablets that must be swallowed whole. They are often used for medications that need to be taken quickly, such as painkillers or asthma inhalers. Mouth-dissolving tablets can also be helpful for patients who have difficulty swallowing pills.
Anti-Psychotics Drug:
Anti-psychotics drug is a group of medicines used to treat mental disorders, such as schizophrenia and bipolar disorder. Anti-psychotics drugs are also used for the treatment of severe depression. They help in decreasing or relieving symptoms such as hallucinations (seeing things that are not there), paranoia (fears without any logical reason), thinking abnormalities, and emotional lability (emotional changes).
Anti-Epileptics Drug:
Anti-epileptics drug is used for the treatment of seizures. Anti-epileptic drugs are also known as antiseizure drugs or anti - epilepsy drugs. They are mainly used to prevent seizures and to reduce the severity of existing ones, but they do not cure them.
Application Insights:
Based on application, the global market is segmented into CNS diseases, gastrointestinal diseases, cardiovascular/vasculitis stroke and others. The other segment includes diabetes and autoimmune disease. In 2017, the CNS diseases dominated the market owing to high incidence of epilepsy and migraine in various regions including North America and Europe.
The gastrointestinal diseases are expected to witness significant growth over the forecast period due to increasing prevalence of chronic conditions such as Crohn¢â‚¬â„¢s disease or ulcerative colitis in various regions including North America Central & South America & Europe Asia Pacific Oceania. According to data published by Inflammatory Bowel Disease Association (IBDA), around 1 million people are suffering from Inflammatory Bowel Disease (IBD) globally which is also known as Crohn¢â‚¬â„¢s disease or Ulcerative Colitis (UC). It has been estimated that about 100000 people in U.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing cases of CVD, diabetes, and other neurological disorders. In addition, presence of major players in this region will also help maintain dominance over this market.
Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period owing to increase in geriatric population and prevalence of chronic diseases such as diabetes which are majorly treated with these tablets. Moreover, growing awareness about mental health issues among people will drive growth further. Increasing number of manufacturing facilities by prominent players for producing generic drugs will also support growth over coming years (see Table 1).
In 2016, India’s generic drug industry recorded an annual revenue worth USD X billion which was higher than that recorded by U S generics industry (USD X billion) and China’s (USD X million).
Growth Factors:
- Increasing prevalence of lifestyle diseases such as diabetes and obesity, which leads to an increase in the demand for mouth-dissolving tablets.
- Rising geriatric population, who are more susceptible to oral health problems, drives the demand for mouth-dissolving tablets.
- Growing awareness about the benefits of using mouth-dissolving tablets over traditional medications drives their adoption among consumers.
- Technological advancements that lead to the development of novel and improved formulations of mouth-dissolving tablets help in expanding their market reach.
Scope Of The Report
Report Attributes
Report Details
Report Title
Mouth-dissolving Tablets Market Research Report
By Type
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
By Application
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
By Companies
Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Mouth-dissolving Tablets Market Report Segments:
The global Mouth-dissolving Tablets market is segmented on the basis of:
Types
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Merck
- Mylan
- Pfizer
- Johnson and Johnson
- GSK
- Otsuka
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Teva
Highlights of The Mouth-dissolving Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
- By Application:
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mouth-dissolving Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mouth-dissolving tablets are a type of medication that dissolve in the mouth. They are used to treat conditions such as GERD (gastroesophageal reflux disease), heartburn, and toothache.
Some of the key players operating in the mouth-dissolving tablets market are Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Teva.
The mouth-dissolving tablets market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mouth-dissolving Tablets Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mouth-dissolving Tablets Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mouth-dissolving Tablets Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mouth-dissolving Tablets Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mouth-dissolving Tablets Market Size & Forecast, 2018-2028
4.5.1 Mouth-dissolving Tablets Market Size and Y-o-Y Growth
4.5.2 Mouth-dissolving Tablets Market Absolute $ Opportunity
Chapter 5 Global Mouth-dissolving Tablets Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Mouth-dissolving Tablets Market Size Forecast by Type
5.2.1 Anti-Psychotics Drug
5.2.2 Anti-Epileptics Drug
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Mouth-dissolving Tablets Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Mouth-dissolving Tablets Market Size Forecast by Applications
6.2.1 CNS Diseases
6.2.2 Gastrointestinal Diseases
6.2.3 CVS Diseases
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mouth-dissolving Tablets Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mouth-dissolving Tablets Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Mouth-dissolving Tablets Analysis and Forecast
9.1 Introduction
9.2 North America Mouth-dissolving Tablets Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Mouth-dissolving Tablets Market Size Forecast by Type
9.6.1 Anti-Psychotics Drug
9.6.2 Anti-Epileptics Drug
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Mouth-dissolving Tablets Market Size Forecast by Applications
9.10.1 CNS Diseases
9.10.2 Gastrointestinal Diseases
9.10.3 CVS Diseases
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Mouth-dissolving Tablets Analysis and Forecast
10.1 Introduction
10.2 Europe Mouth-dissolving Tablets Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Mouth-dissolving Tablets Market Size Forecast by Type
10.6.1 Anti-Psychotics Drug
10.6.2 Anti-Epileptics Drug
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Mouth-dissolving Tablets Market Size Forecast by Applications
10.10.1 CNS Diseases
10.10.2 Gastrointestinal Diseases
10.10.3 CVS Diseases
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Mouth-dissolving Tablets Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Mouth-dissolving Tablets Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Mouth-dissolving Tablets Market Size Forecast by Type
11.6.1 Anti-Psychotics Drug
11.6.2 Anti-Epileptics Drug
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Mouth-dissolving Tablets Market Size Forecast by Applications
11.10.1 CNS Diseases
11.10.2 Gastrointestinal Diseases
11.10.3 CVS Diseases
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Mouth-dissolving Tablets Analysis and Forecast
12.1 Introduction
12.2 Latin America Mouth-dissolving Tablets Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Mouth-dissolving Tablets Market Size Forecast by Type
12.6.1 Anti-Psychotics Drug
12.6.2 Anti-Epileptics Drug
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Mouth-dissolving Tablets Market Size Forecast by Applications
12.10.1 CNS Diseases
12.10.2 Gastrointestinal Diseases
12.10.3 CVS Diseases
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Mouth-dissolving Tablets Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Mouth-dissolving Tablets Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Mouth-dissolving Tablets Market Size Forecast by Type
13.6.1 Anti-Psychotics Drug
13.6.2 Anti-Epileptics Drug
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Mouth-dissolving Tablets Market Size Forecast by Applications
13.10.1 CNS Diseases
13.10.2 Gastrointestinal Diseases
13.10.3 CVS Diseases
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mouth-dissolving Tablets Market: Competitive Dashboard
14.2 Global Mouth-dissolving Tablets Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Merck
14.3.3 Mylan
14.3.4 Pfizer
14.3.5 Johnson and Johnson
14.3.6 GSK
14.3.7 Otsuka
14.3.8 Eli Lilly and Company
14.3.9 AstraZeneca
14.3.10 Bristol-Myers Squibb
14.3.11 Teva
